Skip to main
PVLA

PVLA Stock Forecast & Price Target

PVLA Analyst Ratings

Based on 16 analyst ratings
Strong Buy
Strong Buy 69%
Buy 31%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palvella Therapeutics Inc has a promising outlook due to its lead product candidate, QTORIN rapamycin, which shows a statistically significant improvement in clinical parameters and a strong efficacy profile among patients with rare genetic skin disorders. The company benefits from a targeted approach towards a concentrated patient population, supported by advocacy efforts, which are expected to facilitate quicker market penetration ahead of anticipated competition. Projections indicate substantial potential stock appreciation, with an estimated upside of 70% to 160% in various launch scenarios, indicating strong confidence in the future performance of the company and its innovative therapies.

Bears say

Palvella Therapeutics Inc faces significant challenges in patient identification and access, which may hinder long-term market penetration for its lead product, QTORIN rapamycin. Research indicates a low likelihood of off-label use due to limited support from key opinion leaders and insufficient clinical data, raising concerns about the product's acceptance among payors. Additionally, historical difficulties of oral drugs in achieving effective skin penetration, coupled with a bear scenario projecting a market cap decline, further contribute to the negative outlook on the company's stock.

PVLA has been analyzed by 16 analysts, with a consensus rating of Strong Buy. 69% of analysts recommend a Strong Buy, 31% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palvella Therapeutics Inc (PVLA) Forecast

Analysts have given PVLA a Strong Buy based on their latest research and market trends.

According to 16 analysts, PVLA has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $151.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $151.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palvella Therapeutics Inc (PVLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.